Artelo Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)	Aug. 31, 2021 USD ($)
Marketable securities	$ 3,436,000
Fair Value, Inputs, Level 2 [Member]
Totals marketable securities	3,436
Marketable securities	3,436
Fair Value, Inputs, Level 2 [Member] \| Commercial Paper [Member]
Totals marketable securities	2,724
Marketable securities	2,724
Fair Value, Inputs, Level 2 [Member] \| Asset Backed Securities [Member]
Totals marketable securities	409
Marketable securities	409
Fair Value, Inputs, Level 2 [Member] \| Corporate Debt Securities [Member]
Totals marketable securities	303
Marketable securities	303
Fair Value, Inputs, Level 3 [Member]
Marketable securities	0
Fair Value, Inputs, Level 3 [Member] \| Commercial Paper [Member]
Marketable securities	0
Fair Value, Inputs, Level 3 [Member] \| Corporate Debt Securities [Member]
Marketable securities	0
Fair Value, Inputs, Level 3 [Member] \| Asset-backed securities [Member]
Marketable securities	0
Fair Value, Inputs, Level 1 [Member]
Marketable securities	0
Fair Value, Inputs, Level 1 [Member] \| Commercial Paper [Member]
Marketable securities	0
Fair Value, Inputs, Level 1 [Member] \| Asset-backed securitie [Member]
Marketable securities	0
Fair Value, Inputs, Level 1 [Member] \| Corporate debt securities [Member]
Marketable securities	$ 0